Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2013 | short review

New developments in acute graft-versus-host disease

verfasst von: Hildegard T. Greinix, Margit Mitterbauer, MD, Werner Rabitsch, MD, Nina Worel, MD, Ulrike Just, MD, Robert Knobler, MD, Peter Kalhs, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a well-established curative treatment option for selected patients with hematologic and oncologic diseases. Acute graft-versus-host disease (GvHD) has remained a serious complication of HCT and is associated with high morbidity and mortality especially in patients not responding to first-line therapy with corticosteroids. So far, no standard for salvage therapy of acute corticosteroid-refractory GvHD has been established worldwide. Use of extracorporeal photopheresis results in high response rates, has a steroid-sparing effect and is associated with improved patients’ survival.
Vorheriger Artikel Endpoints in lung cancer trials: today’s challenges for clinical statistics
Nächster Artikel The role of maintenance strategies in lymphoma and CLL

Literatur
1.
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–61.PubMedCrossRef
2.
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.PubMed
3.
Paczesny S, Hanauer D, Sun Y, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45:1–11.PubMedCrossRef
4.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.PubMedCrossRef
5.
Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institute of Health consensus criteria. Blood. 2011;117:3214–9.PubMedCrossRef
6.
Jagasia M, Arora M, Flowers MED, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.PubMedCrossRef
7.
Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant. 2011;17:167–75.PubMedCrossRef
8.
Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health Consensus criteria. Biol Blood Marrow Transplant. 2007;13:1207–15.PubMedCrossRef
9.
Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43:149–53.PubMedCrossRef
10.
Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409–17.PubMedCrossRef
11.
Kuzmina Z, Eder S, Böhm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746–56.PubMedCrossRef
12.
Greinix HT. Graft-versus-host disease. Uni-Med Science. 2008.
13.
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304.PubMedCrossRef
14.
Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Brit J Haematol. 1997;97:855–64.CrossRef
15.
Martin PJ, Rizzo JD, Wingard JR, et al. First and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63.PubMedCrossRef
16.
Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288–93.PubMed
17.
Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–94.PubMedCrossRef
18.
MacMillan M, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7.PubMedCrossRef
19.
Greinix HT, Knobler R. Extracorporeal photopheresis. De Gruyter. 2013.
20.
Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91:405–8.PubMed
21.
Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation. Br J Haematol. 2003;22:118–27.CrossRef
22.
Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265–73PubMedCrossRef
23.
Greinix HT, Worel N, Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1747–8.PubMedCrossRef
24.
Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008;42:609–17.PubMedCrossRef
25.
Calore E, Calo A, Tridello G, et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant. 2008;42:421–5.PubMedCrossRef
26.
Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion. 2010;50:1359–69.PubMedCrossRef
27.
Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Brit J Haematol. 2012;158:30–45.CrossRef
28.
Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease—results from a survey among German-Austrian-Swiss HSCT centers. Biol Blood Marrow Transplant. 2013 Jan 29. doi:pil:S1083-8791(13)00054-2.
Metadaten
Titel
New developments in acute graft-versus-host disease
verfasst von
Hildegard T. Greinix
Margit Mitterbauer, MD
Werner Rabitsch, MD
Nina Worel, MD
Ulrike Just, MD
Robert Knobler, MD
Peter Kalhs, MD
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0080-1

Weitere Artikel der Ausgabe 2/2013

Optimal surveillance strategy of localised testicular non-germ cell sex-cord stromal tumours

  • short review

Broken venous catheter straddling in the pulmonary artery

  • case report

Six years of MEMO: readers survey 2012


  • editorial

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

  • case report

Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

  • special report

CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

  • original report